# New Therapies and Biomarkers for Chagas Infection

> **NCT03981523** · PHASE2 · COMPLETED · sponsor: **University of Texas, El Paso** · enrollment: 450 (actual)

## Conditions studied

- Trypanosoma Cruzi Infection
- Chagas Disease

## Interventions

- **DRUG:** Benznidazole
- **DRUG:** Nifurtimox

## Key facts

- **NCT ID:** NCT03981523
- **Lead sponsor:** University of Texas, El Paso
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-18
- **Primary completion:** 2024-05-29
- **Final completion:** 2024-05-31
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2024-07-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03981523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03981523, "New Therapies and Biomarkers for Chagas Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03981523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*